1. Home
  2. AIHS vs NCEL Comparison

AIHS vs NCEL Comparison

Compare AIHS & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIHS

Senmiao Technology Limited

N/A

Current Price

$15.20

Market Cap

22.6M

Sector

Finance

ML Signal

N/A

NCEL

NewcelX Ltd. Ordinary Shares

N/A

Current Price

$3.49

Market Cap

22.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIHS
NCEL
Founded
2014
2008
Country
China
Switzerland
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.6M
22.0M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
AIHS
NCEL
Price
$15.20
$3.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
262.2K
8.0K
Earning Date
02-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,546,127.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.83
$1.83
52 Week High
$8.26
$5.12

Technical Indicators

Market Signals
Indicator
AIHS
NCEL
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
AIHS
NCEL

About AIHS Senmiao Technology Limited

Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with lease term no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: